Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | FDPS | P14324 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | PTPRB | P23467 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6501640 | 0.86 | ACACB (0.49) | RAB9AALDH1A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL5948337 | 0.83 | CYP3A4 (0.67) | RAB9AALDH1A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL25343200 | 0.83 | ALDH1A1 (0.41) | RAB9AALDH1A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL3242672 | 0.81 | RAB9A (0.45) | RAB9AALDH1A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL27561204 | 0.81 | RAB9A (0.49) | RAB9AALDH1A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL19808628 | 0.81 | HPGD (0.51) | RAB9AALDH1A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL4066043 | 0.80 | NAPRT (0.51) | ALDH1A1CYP3A4CYP2C9CYP2C19FDPS | |
| SCHEMBL27540464 | 0.80 | CYP17A1 (0.53) | RAB9AALDH1A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL27461036 | 0.80 | CYP3A4 (0.50) | ALDH1A1CYP3A4CYP2C9CYP2C19FDPS | |
| SCHEMBL4171208 | 0.80 | ESR1 (0.59) | ALDH1A1CYP3A4CYP2C9CYP2C19TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230058178-A1 | METHODS AND MATERIALS FOR TREATING NERVE INJURY AND/OR PROMOTING WOUND HEALING | UNITED STATES GOVERNMENT | 2023-02-23 | — | — | US | claimed |
| WO-2021150773-A1 | METHODS AND MATERIALS FOR TREATING NERVE INJURY AND/OR PROMOTING WOUND HEALING | THE PENN STATE RESEARCH FOUNDATION (US) | 2021-07-29 | — | — | WO | claimed |
| CN-101723911-B | Method for synthesizing N-aryl-1,3-oxazolin-2-one compounds | UNIV XUZHOU NORMAL | 2012-07-04 | — | — | CN | claimed |
| CN-101723911-A | Method for synthesizing N-aryl-1,3-oxazolin-2-one compounds | UNIV XUZHOU NORMAL | 2010-06-09 | — | — | CN | claimed |
| EP-1567497-B1 | PYRIDINES FOR TREATING INJURED MAMMALIAN NERVE TISSUE | PURDUE RESEARCH FOUNDATION (US) | 2009-09-23 | — | — | EP | claimed |
| US-20080039490-A1 | PYRIDINES FOR TREATING INJURED MAMMALIAN NERVE TISSUE | PURDUE RESEARCH FOUNDATION (US) | 2008-02-14 | — | — | US | claimed |
| WO-2024151969-A1 | POTASSIUM CHANNEL BLOCKERS OR DERIVATIVES THEREOF FOR PREVENTING, ALLEVIATING, AND/OR TREATING MORBIDITY AND MORTALITY INDUCED BY PATHOGENS OR OTHER INDUCERS OF IMMUNE EXHAUSTION AND/OR EXCESS IMMUNE ACTIVATION | UNIVERSITY OF ROCHESTER (US) | 2024-07-18 | — | — | WO | disclosed |
| US-20240058312-A1 | METHODS AND MATERIALS FOR TREATING BONE LOSS | THE PENN STATE RESEARCH FOUNDATION | 2024-02-22 | — | — | US | disclosed |
| US-20240024216-A1 | METHODS AND MATERIALS FOR TREATING HAIR LOSS | THE PENN STATE RESEARCH FOUNDATION | 2024-01-25 | — | — | US | disclosed |
| WO-2024011220-A1 | POTASSIUM CHANNEL BLOCKERS OR DERIVATIVES THEREOF FOR PREVENTING, ALLEVIATING, AND/OR TREATING TISSUE DYSFUNCTION CAUSED BY TOXIC INSULTS | UNIVERSITY OF ROCHESTER (US) | 2024-01-11 | — | — | WO | disclosed |
| EP-4274551-A1 | METHODS AND MATERIALS FOR TREATING BONE LOSS | THE PENN STATE RESEARCH FOUNDATION (US) | 2023-11-15 | — | — | EP | disclosed |
| EP-4274546-A1 | METHODS AND MATERIALS FOR TREATING HAIR LOSS | THE PENN STATE RESEARCH FOUNDATION (US) | 2023-11-15 | — | — | EP | disclosed |
| US-20230346758-A1 | 4-AMINOPYRIDINE (4-AP) AND BONE MORPHOGENETIC PROTEIN 2 (BMP-2) | THE PENN STATE RESEARCH FOUNDATION | 2023-11-02 | — | — | US | disclosed |
| US-20110130429-A1 | PYRIDINES FOR TREATING INJURED MAMMALIAN NERVE TISSUE | PURDUE RESEARCH FOUNDATION (US) | 2011-06-02 | — | — | US | disclosed |
| EP-1751155-B1 | SUBSTITUTED AZACHINAZOLINES HAVING AN ANTIVIRAL ACTION | BAYER HEALTHCARE AG (DE) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007061554-A2 | DOSAGE OF 4-AMINOPYRIDINE DERIVATIVES FOR TREATMENT OF CENTRAL NERVOUS SYSTEM INJURIES | PURDUE RESEARCH FOUNDATION (US) | 2007-05-31 | — | — | WO | disclosed |
| EP-1751155-A1 | SUBSTITUTED AZACHINAZOLINES HAVING AN ANTIVIRAL ACTION | Bayer HealthCare AG (DE) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005113552-A1 | SUBSTITUTED AZACHINAZOLINES HAVING AN ANTIVIRAL ACTION | BAYER HEALTHCARE AG (DE) | 2005-12-01 | — | — | WO | disclosed |
| US-20020052513-A1 | Oxamide IMPDH inhibitors | HOFFMANN-LA ROCHE INC. | 2002-05-02 | — | — | US | disclosed |
| EP-1127883-A2 | Oxamides as IMPDH inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2001-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230346758-A1 | 4-AMINOPYRIDINE (4-AP) AND BONE MORPHOGENETIC PROTEIN 2 (BMP-2) | BMP4, BMP2, BMP1 | RAB9A 1170/4885ALDH1A1 4063/4885CYP3A4 3665/4885 |
| US-20020052513-A1 | Oxamide IMPDH inhibitors | IMPDH1, IMPDH2, IMPA1 | RAB9A 3252/4885ALDH1A1 33/4885CYP3A4 582/4885 |
| US-20240058312-A1 | METHODS AND MATERIALS FOR TREATING BONE LOSS | BMP4, ACP3, COL2A1 | RAB9A 2023/4885ALDH1A1 2236/4885CYP3A4 4340/4885 |
| US-20080039490-A1 | PYRIDINES FOR TREATING INJURED MAMMALIAN NERVE TISSUE | P2RY4, INA, PMP22 | RAB9A 3684/4885ALDH1A1 298/4885CYP3A4 2178/4885 |
| US-20240024216-A1 | METHODS AND MATERIALS FOR TREATING HAIR LOSS | BMP4, S100A4, S100B | RAB9A 3706/4885ALDH1A1 203/4885CYP3A4 3723/4885 |
| US-20110130429-A1 | PYRIDINES FOR TREATING INJURED MAMMALIAN NERVE TISSUE | PMP22, SMN1; SMN2, MUSK | RAB9A 2051/4885ALDH1A1 256/4885CYP3A4 3082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.